Technology transfer / Localization · Latin America · Announced 21 Oct 2026
Samsung Bioepis → Bionovis
Bionovis is the private Brazilian partner, alongside state lab Bahiafarma, in Samsung Bioepis's 10-year PDP to supply and then locally manufacture the eculizumab biosimilar SB12 for the SUS from 2027.
Parties: Samsung Bioepis (South Korea) → Bionovis (Brazil)
- Deal type
- Technology transfer / Localization
- Value
- Undisclosed
- Territory
- Brazil — supply to the public health system (SUS) under a Productive Development Partnership
- Therapeutic area
- Rare / Orphan
- Asset
- SB12 (eculizumab)
- Announced
- 21 Oct 2026
Our analysis
Why this matters
Samsung Bioepis announced on 21 October 2026 a 10-year Productive Development Partnership (PDP) to supply SB12, its eculizumab biosimilar, to Brazil's public health system (SUS) from 2027. Bionovis, a local pharmaceutical company, is one of two Brazilian partners; the other is the state laboratory Bahiafarma (listed separately). Manufacturing moves gradually from Samsung Bioepis to the partners. No value was disclosed.
Brazilian public spending on eculizumab exceeded BRL 947 million (about US$171 million) in 2025, according to IQVIA data cited by the company.
The full analysis is free to read with a work email on this page.
Source: BioSpectrum Asia